BriaCell Therapeutics Corp. reported preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-OTS+? and Bria-PROS+?, in a poster session during the 2024 American Association for Cancer Research (AACR) Annual Meeting held from April 5-10 at San Diego Convention Center, San Diego, CA.

BriaCell has designed Bria-OTS+?, an immunotherapy platform representing the next generation (enhanced version) of Bria-OTS?, BriaCell?s personalized off-the-shelf (i.e. pre-manufactured and ready for use) immunotherapy for cancer. Bria-OTS+? immunotherapy expresses multiple immune activating cytokines and co-stimulatory molecules in addition to immune boosting granulocyte-macrophage colony-stimulating factor (GM-CSF).

BriaCell expects to use Bria-OTS+? and Bria-PROS+? in its upcoming phase 1/2a clinical studies for breast and prostate cancer, respectively.

Bria-PROS+? has already entered GMP manufacturing to generate clinical supplies for the phase 1/2a study. The characteristics of the next generation Bria-OTS+?

immunotherapy platform include the following: Bria-OTS+? and Bria-PROS+? activate key components of the innate immune system which serves as the body?s first line of defense against cancer, Bria-OTS+?

and Bria-PROS+? engage multiple facets of the adaptive immune response. This may result in lasting anti-cancer effects in patients, Specifically activates Natural Killer (NK) cells to counter cancer immune escape caused by the loss of human leukocyte antigens (HLA), Designed for personalized and ready-to-use therapy with long term stability, Simplified administration process of intradermal inoculations (injection into the skin) allows administration in a physician?s office, Anticipated to have a favorable side effect profile, indicating good tolerance (based on prior findings with Bria-IMT?).